J. Taieb

B. Nordlinger, P. Rougier, J. Vaillant, 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives.

P. Laurent-Puig, J. Taieb, T. Aparicio, 2016, Clinics and research in hepatology and gastroenterology.

Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review

G. Prager, A. Stein, J. Taieb, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial

J. Taieb, L. Bedenne, P. Puig, 2008, Expert review of anticancer therapy.

Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial

A. Luciani, C. Tournigand, I. Sobhani, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials.

M. Ducreux, O. Bouché, J. Taieb, 2021, European journal of cancer.

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.

N. Wolmark, R. Goldberg, J. Marshall, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey.

C. Tournigand, J. Taieb, C. Neuzillet, 2020, Clinical colorectal cancer.

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial

J. Weitz, P. Laurent-Puig, F. Cianchi, 2019, Annals of Surgical Oncology.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

M. Ychou, G. Deplanque, Y. Bécouarn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".

O. Bouché, D. Vernerey, J. Taieb, 2022, Clinical colorectal cancer.

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer

R. Guimbaud, J. Taieb, A. Hollebecque, 2022, Cancers.

Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer

R. Guimbaud, J. Taieb, S. Pernot, 2022, Frontiers in Medicine.

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study

E. Van Cutsem, L. Wyrwicz, T. Price, 2020, ESMO Open.

Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.

D. Vernerey, P. Hammel, J. Taieb, 2020, Clinical colorectal cancer.

Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.

M. Peeters, J. Taieb, A. Cervantes, 2018, Future oncology.

What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey

J. Taieb, P. Michel, C. Penna, 2020, World Journal of Surgery.

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study

E. Van Cutsem, J. Tabernero, A. Grothey, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study.

J. Taieb, C. Coutzac, S. Pernot, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status

C. Köhne, M. Peeters, F. Rivera, 2017, Clinical colorectal cancer.

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial

F. Brunetti, A. Lièvre, C. Lepage, 2021, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer.

C. Cheze-le Rest, P. Laurent-Puig, H. Sokol, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

D. Vernerey, J. Taieb, R. Coriat, 2020, International journal of cancer.

Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers

P. Laurent-Puig, B. Rance, H. Blons, 2021, Cancers.

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

C. Borel, C. Lepage, V. Boige, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.

C. Lepage, F. Ghiringhelli, J. Raoul, 2018, European journal of cancer.

Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

V. Gebski, P. Gibbs, F. Lammert, 2018, Clinical colorectal cancer.

Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials

J. Canon, M. Peeters, G. Pentheroudakis, 2018, British Journal of Cancer.

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.

T. de Baère, M. Ducreux, C. Lepage, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.

V. Bourgeois, J. Taieb, M. Scartozzi, 2022, European journal of cancer.

Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.

D. Sargent, S. Thibodeau, P. Laurent-Puig, 2015 .

Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database.

P. Cheung, J. Taieb, D. Neasham, 2021, Future oncology.

Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?

D. Thabut, J. Taieb, T. Poynard, 2003, Journal of hepatology.

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Y. Bang, Z. Wainberg, J. Taieb, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment improvement by addition of leucovorin to S-1 plus oxaliplatin in patients with advanced gastric cancer

J. Taieb, S. Pernot, A. Zaanan, 2016 .

Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E‐mutated and microsatellite unstable metastatic colorectal cancer patient: A case report

S. Garinet, J. Taieb, A. Zaanan, 2021, Genes, chromosomes & cancer.

Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'

J. Taieb, J. Bachet, S. Pernot, 2016, British journal of cancer.

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).

C. Lepage, J. Taieb, R. Coriat, 2020, European journal of cancer.

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.

M. Ducreux, P. Rougier, O. Bouché, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Chemosensitivity in ovarian metastases from gastric cancer: a case series.

P. Rougier, J. Taieb, A. Berger, 2013, Clinics and research in hepatology and gastroenterology.

Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries

M. Pocard, J. Taieb, A. Zaanan, 2020, Pleura and peritoneum.

Immune therapy in colorectal cancer

E. Tartour, J. Taieb, T. Voron, 2017 .

Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays

D. Harats, M. Karpasas, A. Porgador, 2011, PloS one.

The dialogue between natural killer cells and dendritic cells

L. Zitvogel, H. Wakasugi, C. Borg, 2005 .

Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.

M. Housset, P. Rougier, J. Belghiti, 2011, World journal of gastroenterology.

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

R. Labianca, J. Meyerhardt, E. Oki, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials

P. Laurent-Puig, H. Blons, A. de Reyniès, 2021, British Journal of Cancer.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

O. Bouché, F. Retornaz, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial

P. Laurent-Puig, O. Bouché, T. Mazard, 2021, Clinical Cancer Research.

Author Correction: Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer

A. Burgun, J. Bibault, P. Giraud, 2018, Scientific Reports.

Digestive neuroendocrine tumors (DNET): the era of targeted therapies.

P. Rougier, J. Taieb, C. Lepère, 2013, Clinics and research in hepatology and gastroenterology.

Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma

P. Couzigou, J. Taieb, P. Merle, 2017, ESMO Open.

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma

C. Lepage, J. Taieb, J. Bachet, 2022, The oncologist.

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study

A. Carrato, D. Melisi, G. Prager, 2020, ESMO Open.

Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer.

A. Carrato, D. Melisi, G. Prager, 2021, Future oncology.

How I treat pancreatic cancer

J. Taieb, R. Abdallah, 2020, ESMO open.

Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer.

V. Gebski, P. Gibbs, A. Gray, 2017 .

Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer

L. Zitvogel, G. Kroemer, E. Tartour, 2012, Oncoimmunology.

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study

P. Laurent-Puig, H. Blons, O. Bouché, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

J. Blay, L. Zitvogel, N. Chaput, 2016 .

CD4 regulatory T cells inhibit natural killer cell functions in a transforming growth factor– (cid:1) –dependent manner

J. Blay, L. Zitvogel, N. Chaput, 2005 .

CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification

P. Laurent-Puig, A. Reyniès, A. de Reyniès, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Whose side are you on?

J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.

N. Loménie, A. Lièvre, P. Laurent-Puig, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Loss of SMARCB1 expression in colon carcinoma.

O. Delattre, C. Lepage, J. Mosnier, 2020, Cancer biomarkers : section A of Disease markers.

Transarterial treatment approaches of hepatocellular carcinoma

J. Taieb, O. Pellerin, M. Sapoval, 2010 .

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

O. Bouché, F. Retornaz, J. Taieb, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis

P. Pereira, T. de Baère, T. Helmberger, 2020, CardioVascular and Interventional Radiology.

Checkpoint inhibitors and gastrointestinal immune-related adverse events

J. Taieb, T. Ramtohul, S. Pernot, 2016, Current opinion in oncology.

Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.

L. Zitvogel, N. Chaput, F. Lemonnier, 2006, The Journal of Immunology.

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines1

L. Zitvogel, N. Chaput, F. Lemonnier, 2006, The Journal of Immunology.

Based Vaccines Cyclophosphamide Synergizes with Exosome Chemoimmunotherapy of Tumors:

L. Zitvogel, N. Chaput, F. Lemonnier, 2006 .

The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions

P. Laurent-Puig, J. Galon, J. Taieb, 2020, Oncoimmunology.

Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.

S. Novello, E. Raymond, J. Armand, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.

J. Taieb, M. Svrcek, D. Tougeron, 2022, European journal of cancer.

Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment.

J. Canon, M. Peeters, T. Price, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)

P. Laurent-Puig, F. Penault-Llorca, J. Tabernero, 2016 .

Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of the National Cancer Institute.

Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer.

E. Thervet, J. Taieb, A. Karras, 2021, European journal of cancer.

Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.

J. Vaillant, A. Sauvanet, J. Taieb, 2019, Clinics and research in hepatology and gastroenterology.

LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer

J. Tabernero, A. Grothey, R. Yaeger, 2020 .

Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer

E. Van Cutsem, J. Tabernero, R. Yaeger, 2021, Annals of Oncology.

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).

P. Laurent-Puig, P. Rougier, O. Bouché, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL.

P. Pereira, T. de Baère, T. Helmberger, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

R. Labianca, J. Meyerhardt, D. Sargent, 2017 .

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019 .

Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.

N. Wolmark, E. Van Cutsem, R. Goldberg, 2019, Journal of Clinical Oncology.

Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.

J. Taieb, D. Fuks, C. Gallois, 2022, Clinics and research in hepatology and gastroenterology.

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

C. Borg, B. Buecher, O. Bouché, 2018, The Lancet. Oncology.

Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability.

F. Caroli-Bosc, G. Piessen, M. Perrier, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

533PA large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability

J. Taieb, R. Coriat, T. André, 2017 .

Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.

E. Van Cutsem, R. Goldberg, D. Haller, 2020 .

Efficacy of anti-EGFR in MSI metastatic colorectal cancer depending on sporadic or familial origin.

D. Vernerey, J. Taieb, M. Svrcek, 2020, Journal of the National Cancer Institute.

FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM.

F. Fein, F. Bonnetain, J. Taieb, 2012 .

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019, Journal of Clinical Oncology.

Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens

P. Rougier, J. Taieb, O. Pellerin, 2015 .

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

R. Labianca, J. Meyerhardt, M. Buyse, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

M. Ychou, G. Deplanque, Y. Bécouarn, 2017 .

Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort.

D. Aust, R. Salazar, P. Laurent-Puig, 2017 .

Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.

J. Tabernero, M. Fakih, F. Ciardiello, 2021, Future oncology.

JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Y. Bang, Keun-Wook Lee, C. Yen, 2018 .

LBA21_PRProspective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)

R. Labianca, J. Meyerhardt, D. Sargent, 2017 .

Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial.

J. Taieb, N. Boku, J. Gurtler, 2016 .

Malnutrition Is High and Underestimated During Chemotherapy in Gastrointestinal Cancer: An AGEO Prospective Cross-Sectional Multicenter Study

J. Sabate, F. Bonnetain, J. Taieb, 2012, Nutrition and cancer.

IL‐2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes

L. Zitvogel, N. Chaput, C. Lebbé, 2005, European journal of immunology.

Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

M. Ychou, P. Rougier, T. Mazard, 2014, Gastric Cancer.

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

I. Sobhani, P. Laurent-Puig, F. Bonnetain, 2013, British Journal of Cancer.

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.

E. Tartour, J. Taieb, A. Carpentier, 2013, Cancer research.

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer

E. Tartour, J. Taieb, M. Terme, 2013, Oncoimmunology.

Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.

C. Borel, V. Boige, O. Bouché, 2016 .

FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study

C. Tournigand, M. Perrier, D. Botsen, 2022, International journal of cancer.

Therapy Imatinib and IL-2 Effects Mediated by the Combination The Critical Role of IL-15 in the Antitumor

N. Chaput, M. Ferrantini, J. Taieb, 2013 .

Scientific Societies Should Start Sponsoring Observational Studies

P. Pereira, V. Vilgrain, T. de Baère, 2020, CardioVascular and Interventional Radiology.

Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8.

D. Aust, R. Salazar, P. Laurent-Puig, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.

V. Gebski, P. Gibbs, V. Heinemann, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.

M. Shah, E. Van Cutsem, J. Tabernero, 2022, Clinical colorectal cancer.

Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.

P. Laurent-Puig, F. Puglisi, C. Lepage, 2020, Clinics and research in hepatology and gastroenterology.

Monday, 27 August 2012

V. V. Ivanenko, E. A. Medvedeva, Michail I. Papafaklis, 2012 .

A Case of 5‐FU‐Related Severe Toxicity Associated with the p.Y186C DPYD Variant

M. Loriot, J. Taieb, A. Zaanan, 2014, Clinical pharmacology and therapeutics.

Bridge to surgery after irinotecan-based liver chemoembolization for metastatic gastric adenocarcinoma: Letter to the editor.

J. Taieb, T. Méatchi, O. Pellerin, 2020, Clinics And Research in Hepatology and Gastroenterology.

Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).

P. Laurent-Puig, R. Goldberg, T. Smyrk, 2019, Journal of Clinical Oncology.

Breast cancer: precancerous lesions

S. Fosså, P. Johnston, Alberto Costa, 2006 .

Adequate SIRT activity dose is as important as adequate chemotherapy dose - Authors' reply.

P. Gibbs, Ricky A. Sharma, J. Moschandreas, 2017, The Lancet. Oncology.

528PAFLIBERCEPT + FOLFIRI FOR TREATMENT OF METASTATIC COLORECTAL CANCER AFTER OXALIPLATIN FAILURE: 4TH INTERIM SAFETY DATA FROM THE GLOBAL AFLIBERCEPT SAFETY AND QUALITY-OF-LIFE PROGRAM (ASQOP/AFEQT STUDIES).

V. Heinemann, J. Taieb, A. Sobrero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): Results of the phase II study ERGO

M. Hebbar, J. Taieb, T. Poynard, 2007 .

Métastase pancréatique métachrone d'un adénocarcinome rectal : à propos d'un cas Pancreatic metastasis from a colorectal cancer: a case-report

P. Rougier, J. Taieb, B. Landi, 2011 .

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

O. Bouché, A. Bedjaoui, F. Retornaz, 2018, European journal of cancer.

Truth Survival in Clinical Research: An Evidence-Based Requiem?

Julien Taieb, J. Taieb, T. Poynard, 2002, Annals of Internal Medicine.

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

P. Laurent-Puig, M. Ychou, G. Deplanque, 2019, Annals of Oncology.

Mechanisms of alcoholic liver disease: cytokines.

D. Brenner, R. Cameron, B. Rehermann, 2001, Alcoholism, clinical and experimental research.

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer

P. Laurent-Puig, C. Montagut, M. Peeters, 2019, Drugs.

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis

Arunandan Kumar, H. Hochster, J. Taieb, 2023, Therapeutic advances in medical oncology.

Hepatocellular carcinoma (HCC): an update.

P. Rougier, J. Taieb, E. Mitry, 2007, Seminars in oncology.

Medical treatments for hepatocellular carcinoma (HCC): what's next?

P. Rougier, J. Taieb, J. Barbare, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.

P. Laurent-Puig, D. Vernerey, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors

M. Bureau, L. Zitvogel, E. Tartour, 2013, Science Translational Medicine.

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

E. Van Cutsem, M. Alsina, M. Lichinitser, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge.

Anne Berger, Simon Pernot, Julien Taieb, 2015, World journal of gastroenterology.

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

T. Conroy, J. Lacy, P. Allen, 2016, The Lancet. Oncology.

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.

J. Ajani, Y. Bang, J. Taieb, 2018, Cancer treatment reviews.

BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma.

P. Laurent-Puig, H. Blons, A. Bats, 2022, Clinics and research in hepatology and gastroenterology.

Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

R. Labianca, R. Salazar, P. Laurent-Puig, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).

F. Brunetti, A. Lièvre, C. Lepage, 2020, Annals of surgery.

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.

A. Lièvre, M. Ychou, O. Bouché, 2016, Clinical colorectal cancer.

O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial

L. Collette, P. Laurent-Puig, E. Van Cutsem, 2012 .

Colorectal Cancer: Why Does Side Matter?

J. Taieb, S. Pernot, A. Zaanan, 2018, Drugs.

Incidence of KRAS status in ongoing adjuvant trials in colon cancer

P. Laurent-Puig, S. Alberts, J. Taieb, 2009 .

Immunomodulatory Activity of VEGF in Cancer.

E. Tartour, J. Taieb, T. Voron, 2017, International review of cell and molecular biology.

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

P. Laurent-Puig, D. Vernerey, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

M. Ducreux, A. Cazes, C. Borg, 2017, European journal of cancer.

Arterial vascularization of the right colon with implications for surgery

J. Taieb, I. Ben Abdallah, J. Chevallier, 2019, Surgical and Radiologic Anatomy.

Inter-mesenteric connections between the superior and inferior mesenteric arteries for left colonic vascularization: implications for colorectal surgery

J. Taieb, A. Berger, J. Chevallier, 2018, Surgical and Radiologic Anatomy.

Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.

P. Laurent-Puig, J. Taieb, V. Taly, 2020, Cancer treatment reviews.

Prognostic value of the PrPC-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype

P. Laurent-Puig, S. Dedhar, J. Launay, 2021, Oncoimmunology.

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer

P. Laurent-Puig, H. Blons, J. Launay, 2019, EBioMedicine.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

L. Collette, R. Salazar, P. Laurent-Puig, 2014, The Lancet. Oncology.

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

D. Aust, R. Salazar, P. Laurent-Puig, 2021, Clinical Cancer Research.

Title: Intra-tumor CMS heterogeneity impacts patient prognosis in localized colon cancer Short title: Intra-tumoral heterogeneity in colon cancer

D. Aust, R. Salazar, P. Laurent-Puig, 2021 .

Adjuvant Chemotherapy for Stage III Colon Cancer

J. Taieb, C. Gallois, 2020, Cancers.

A comprehensive overview of promising biomarkers in stage II colorectal cancer.

J. Taieb, M. Svrcek, T. André, 2020, Cancer treatment reviews.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study

C. Lepage, J. Emile, F. Ghiringhelli, 2019, Gut.

Exploring the best treatment options for BRAF-mutant metastatic colon cancer

J. Taieb, A. Zaanan, A. Lapeyre-Prost, 2019, British Journal of Cancer.

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials

T. Hickish, R. Salazar, J. Tabernero, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).

C. Lepage, R. Guimbaud, V. Boige, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status

R. Salazar, P. Laurent-Puig, E. Van Cutsem, 2017, JAMA oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Salazar, P. Laurent-Puig, E. Van Cutsem, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[Management of hepatocellular carcinoma. Where are we now? What's next?].

J. Zucman‐Rossi, T. Baère, D. Franco, 2009, Bulletin du cancer.

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

E. Tartour, W. Fridman, S. Oudard, 2011, Cancer and Metastasis Reviews.

Biomarkers for Immunotherapy in Gastrointestinal Cancers

J. Taieb, A. Zaanan, J. Palle, 2021, Cancer Immunotherapy.

Modulation of Immunity by Antiangiogenic Molecules in Cancer

E. Tartour, J. Taieb, E. Marcheteau, 2012, Clinical & developmental immunology.

FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort

F. Carbonnel, J. Blanc, J. Taieb, 2014, Annals of Surgical Oncology.

Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.

D. Sargent, P. Laurent-Puig, R. Goldberg, 2015 .

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

E. Tartour, J. Taieb, A. Berger, 2015, The Journal of experimental medicine.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy

P. Laurent-Puig, J. Tabernero, C. Lepage, 2018, Clinical Cancer Research.

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

D. Sargent, F. Penault-Llorca, R. Goldberg, 2017, Journal of the National Cancer Institute.

Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

A. Lièvre, J. Taieb, D. Tougeron, 2022, British Journal of Cancer.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.

N. Siauve, P. Rougier, J. Taieb, 2014, Clinics and research in hepatology and gastroenterology.

French Intensive Care Society, International congress – Réanimation 2016

Paul P. Tallon, Stéphane Huot, B. Souweine, 2016, Annals of Intensive Care.

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives

P. Laurent-Puig, S. Garinet, J. Taieb, 2021, Cancers.

ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, A. Grothey, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The area between ROC curves, a non‐parametric method to evaluate a biomarker for patient treatment selection

Fabien Subtil, Muriel Rabilloud, Pierre Laurent-Puig, 2020, Biometrical journal. Biometrische Zeitschrift.

Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?

P. Laurent-Puig, J. Taieb, 2008, Current opinion in oncology.

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

P. Laurent-Puig, J. Tabernero, C. Lepage, 2016, JAMA oncology.

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.

J. Tabernero, F. Ciardiello, T. Seufferlein, 2016, The oncologist.

Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study

J. Kleeff, C. Bassi, T. Keck, 2022, Annals of Surgical Oncology.

Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study

M. Petrova, J. Taieb, Anthony Lopez, 2021, Cancers.

Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.

M. Peeters, T. Price, F. Rivera, 2019, Clinical colorectal cancer.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

C. Reinhold, C. Borel, C. Lepage, 2019, Gut.

Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma.

J. Taieb, A. Berger, C. Lagorce-Pagès, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

A novel dendritic cell subset involved in tumor immunosurveillance

P. Opolon, L. Zitvogel, G. Kroemer, 2006, Nature Medicine.

Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue

N. Chaput, D. Klatzmann, J. Vaillant, 2008, Gut.

Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database

B. Rance, S. Katsahian, J. Taieb, 2022, Cancers.

Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort

J. Taieb, R. Coriat, J. Bachet, 2021, British Journal of Cancer.

Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol

T. de Baère, C. Dromain, V. Boige, 2020, BMC Cancer.

Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.

J. Taieb, D. Tougeron, S. Pernot, 2020, Clinics and research in hepatology and gastroenterology.

Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial

C. Tournigand, F. Bonnetain, P. Hammel, 2019, Cancer medicine.

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study

D. Pezet, J. Taieb, D. Tougeron, 2019, Therapeutic advances in gastroenterology.

Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC).

T. Conroy, O. Bouché, P. Hammel, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort

J. Vaillant, A. Sauvanet, O. Hentic, 2018, Annals of Surgical Oncology.

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

F. Fein, F. Bonnetain, J. Taieb, 2015, PloS one.

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

J. Taieb, T. Aparicio, M. Gauthier, 2014, BMC Cancer.

Colorectal cancer and immunity: what we know and perspectives.

E. Tartour, J. Taieb, T. Voron, 2014, World journal of gastroenterology.

Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives.

J. Taieb, T. André, E. Auclin, 2019, Cancer treatment reviews.

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

C. Borg, B. Buecher, O. Bouché, 2022, European Journal of Cancer.

Immunity and squamous cell carcinoma of the anus: epidemiological, clinical and therapeutic aspects.

E. Tartour, J. Taieb, S. Pernot, 2014, Clinics and research in hepatology and gastroenterology.

Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα

Laurence Zitvogel, Julien Taieb, Caroline Robert, 2009, PloS one.

Does Bead Size Affect Patient Outcome in Irinotecan-Loaded Beads Chemoembolization Plus Systemic Chemotherapy Regimens for Liver-Dominant Colorectal Cancer? Results of an Observational Study

J. Taieb, O. Pellerin, M. Sapoval, 2020, CardioVascular and Interventional Radiology.

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

P. Bachellier, C. Borg, D. Vernerey, 2016, BMC Cancer.

Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men

S. Grabar, J. Taieb, H. Péré, 2018, British Journal of Cancer.

Factors associated with anal cancer screening uptake in men who have sex with men living with HIV: a cross-sectional study.

S. Grabar, J. Taieb, H. Péré, 2019, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study

P. Laurent-Puig, A. Sauvanet, J. Emile, 2019, British Journal of Cancer.

Sarcopenia Is Linked to Treatment Toxicity in Patients With Metastatic Colorectal Cancer

Julien Taieb, Aziz Zaanan, J. Taieb, 2014, Nutrition and cancer.

Should mismatch repair status be determined in all stage II and III colon cancer patients

J. Taieb, A. Zaanan, 2014 .

Therapeutic implications of DNA mismatch repair in adjuvant colorectal cancer chemotherapy

P. Laurent-Puig, J. Taieb, O. Dubreuil, 2013 .

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.

E. Van Cutsem, J. Tabernero, F. Ciardiello, 2023, Cancer treatment reviews.

Methylator phenotype in colorectal cancer: A prognostic factor or not?

P. Laurent-Puig, J. Taieb, C. Gallois, 2016, Critical reviews in oncology/hematology.

Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).

J. Emile, F. Ghiringhelli, D. Vernerey, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Dendritic cell derived‐exosomes: biology and clinical implementations

L. Zitvogel, N. Chaput, F. André, 2006, Journal of leukocyte biology.

Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology

F. Fein, F. Bonnetain, J. Taieb, 2016, Quality of Life Research.

Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort

P. Innominato, O. Hentic, J. Blanc, 2015, Annals of Surgical Oncology.

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

E. Tartour, F. Penault-Llorca, N. Radosevic-Robin, 2019, Gastric Cancer.

Sandoval the Growth of Mucosal Tumors T Cells Is Crucial to Inhibit + Mucosal Imprinting of Vaccine-Induced CD 8

M. Bureau, L. Zitvogel, E. Tartour, 2013 .

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.

R. Labianca, J. Meyerhardt, V. Torri, 2020, The Lancet. Oncology.

Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial

L. Collette, P. Laurent-Puig, C. Lepage, 2012 .

Title : VEGF-A inhibition prevents tumor-induced Treg proliferation

E. Tartour, J. Taieb, A. Carpentier, 2012 .

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

C. Tournigand, F. Bonnetain, P. Hammel, 2017, The lancet. Gastroenterology & hepatology.

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study

J. Taieb, J. Bachet, K. Le Malicot, 2018, British Journal of Cancer.

Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003.

Tae Won Kim, J. Taieb, T. Yoshino, 2021, Future oncology.

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma

M. Hebbar, J. Taieb, T. Poynard, 2008, Cancer.

Outcomes in elderly patients admitted to the intensive care unit with solid tumors

S. Oudard, S. Katsahian, J. Taieb, 2017, Annals of Intensive Care.

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR).

Y. Bécouarn, J. Emile, F. Bibeau, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

What treatment in 2017 for inoperable pancreatic cancers?

M. Reni, F. Lordick, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study

J. Taieb, J. Bachet, K. Le Malicot, 2018, British Journal of Cancer.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

V. Gebski, P. Gibbs, F. Lammert, 2017, The Lancet. Oncology.

Safety and efficacy of immunotherapy according to the age threshold of 80 years.

S. Oudard, J. Taieb, E. Paillaud, 2023, Bulletin du cancer.

Impact of sarcopenia and visceral fat on postoperative morbidity and survival after rectal cancer surgery in patients treated with neoadjuvant chemoradiotherapy

J. Taieb, V. Roblot, G. Manceau, 2023, Surgery Open Digestive Advance.

Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study.

A. Lièvre, J. Taieb, S. Pernot, 2019, European journal of cancer.

Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells.

L. Zitvogel, G. Kroemer, N. Chaput, 2007, Cancer research.

Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues Oncologues

A. Lièvre, W. Cacheux, J. Taieb, 2015, Cancer.

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer

R. Goldberg, Z. Wainberg, C. Montagut, 2018, ESMO Open.

REDEFINING LATER-LINE THERAPY IN METASTATIC COLORECTAL CANCER This symposium took place on 29 th June 2017 as part of the 19 th World Congress on Gastrointestinal Cancer in Barcelona , Spain Chairpersons

Speakers, M. Peeters, J. Taieb, 2017 .

LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial

P. Laurent-Puig, C. Lepage, C. Borg, 2022, Annals of Oncology.

433P Durvalumab and tremelimumab in combination with FOLFOX in patients with previously untreated RAS-mutated metastatic colorectal cancer: First results of efficacy at one year for phase II MEDITREME trial

C. Borg, A. Bertaut, Jean-David Fumet, 2021, Annals of Oncology.

Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer

A. Burgun, J. Bibault, P. Giraud, 2018, Scientific Reports.

Prognostic score for synchronous metastatic rectal cancer: A real-world study.

A. Lièvre, R. Guimbaud, O. Bouché, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The “Immunoscore” in rectal cancer: could we search quality beyond quantity of life?

T. Hansen, J. Galon, G. Beets, 2021, Oncotarget.

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)

P. Laurent-Puig, N. Siauve, H. Blons, 2017, Clinical Cancer Research.

Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives

J. Lindberg, J. Taieb, L. Benhaim, 2022, Acta oncologica.

Advances in management of adjuvant chemotherapy in rectal cancer: Consequences for clinical practice.

C. Durdux, J. Taieb, A. Berger, 2016, Clinics and research in hepatology and gastroenterology.

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors

L. Pusztai, A. Grothey, Z. Demko, 2022, JCO precision oncology.

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer

P. Validire, B. Gayet, H. Blons, 2019, Cellular Oncology.

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.

Y. Bang, Z. Wainberg, Keun-Wook Lee, 2019, Future oncology.

Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study.

J. Desai, G. Folprecht, H. Wasan, 2022, Clinical colorectal cancer.

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

M. Peeters, M. Valladares-Ayerbes, F. Rivera, 2017, Journal of Cancer Research and Clinical Oncology.

Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study

G. Prager, R. Guimbaud, L. Mineur, 2023, Gastric Cancer.

A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification.

J. Meyerhardt, I. Nagtegaal, J. Tabernero, 2021, Cancer treatment reviews.

MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

M. Salto‐Tellez, F. Nicolantonio, A. Bardelli, 2016 .

DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.

R. Greil, R. Salazar, P. Laurent-Puig, 2016, JAMA oncology.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Karin Haustermans, Simone Mathoulin-Pélissier, Julien Taieb, 2014, European journal of cancer.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

T. Hickish, J. Tabernero, D. Vernerey, 2019, British Journal of Cancer.

Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial.

F. Cianchi, C. Lepage, J. Taieb, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial

A. Luciani, I. Sobhani, K. Leroy, 2015, BMC Cancer.

Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.

D. Sargent, P. Laurent-Puig, R. Goldberg, 2020, JCO precision oncology.

Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study

A. Lièvre, P. Hammel, J. Taieb, 2022, International journal of cancer.

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

R. Labianca, J. Meyerhardt, E. Oki, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).

G. Chatellier, P. Laurent-Puig, H. Blons, 2021, European journal of cancer.

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.

E. Van Cutsem, J. Tabernero, M. Fakih, 2023, Journal of Clinical Oncology.

FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).

C. Borg, O. Bouché, F. Ghiringhelli, 2015 .

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study

O. Bouché, F. Bonnetain, J. Taieb, 2017, Oncotarget.

The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients’ characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.

Y. Bécouarn, O. Bouché, F. Bonnetain, 2016 .

A novel mode of antitumor activity for imatinib mesylate: Consequences for the design of surrogate markers of efficacy and combination therapies

L. Zitvogel, N. Chaput, M. Heinrich, 2005 .

Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients

E. Tartour, F. Ghiringhelli, J. Taieb, 2021, Cancers.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2020 .

A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency.

Z. Szallasi, F. Ginhoux, P. Vandenabeele, 2020, Cancer discovery.

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma

C. Borg, B. Buecher, O. Bouché, 2020, Therapeutic advances in medical oncology.

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

Role of circulating tumor DNA in the management of patients with colorectal cancer.

P. Laurent-Puig, H. Blons, J. Taieb, 2018, Clinics and research in hepatology and gastroenterology.

Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.

J. Taieb, B. Landi, J. Bachet, 2011, Clinics and research in hepatology and gastroenterology.

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer

P. Validire, B. Gayet, H. Blons, 2019, Cellular Oncology.

Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.

P. Laurent-Puig, R. Goldberg, T. Smyrk, 2020, European Journal of Cancer.

Ampullary carcinoma prognostic markers

P. Laurent-Puig, J. Taieb, G. Perkins, 2019, Oncotarget.

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European journal of cancer.

CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).

M. Shah, A. Grothey, R. Xu, 2017 .

Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study

J. Taieb, D. Tougeron, P. Artru, 2018, Targeted Oncology.

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.

N. Tomita, T. Yamanaka, N. Wolmark, 2021, Journal of the National Cancer Institute.

Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.

R. Labianca, R. Goldberg, C. Lepage, 2022, European journal of cancer.

LBA-006Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy.

P. Gibbs, V. Heinemann, M. Peeters, 2017, Annals of Oncology.

Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy.

P. Gibbs, V. Heinemann, M. Peeters, 2017, Annals of Oncology.

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy

L. Wyrwicz, T. Price, J. Taieb, 2023, BMC Cancer.

The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

D. Thabut, R. Moreau, J. Taieb, 2006, Journal of hepatology.

Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.

M. Loriot, N. Pallet, V. Boige, 2022, European journal of cancer.

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency

M. Loriot, H. Blons, N. Pallet, 2020, British Journal of Cancer.

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency

M. Loriot, H. Blons, N. Pallet, 2020, British Journal of Cancer.

Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives.

M. Loriot, N. Pallet, J. Taieb, 2023, Clinica chimica acta; international journal of clinical chemistry.

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study

P. Laurent-Puig, H. Blons, O. Bouché, 2019, Cancers.

Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.

S. Truant, T. de Baère, M. Ducreux, 2016, European journal of cancer.

International experts’ panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.

R. Labianca, L. Collette, D. Aust, 2012 .

Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of Oncology.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study.

P. Laurent-Puig, H. Blons, O. Bouché, 2017 .

Safety, Feasibility and Technical Considerations from a Prospective, Observational Study—CIREL: Irinotecan-TACE for CRLM in 152 Patients

P. Pereira, T. Helmberger, P. Lucatelli, 2022, Journal of clinical medicine.

Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.

J. Taieb, O. Pellerin, E. Watkin, 2015, Clinics and research in hepatology and gastroenterology.

Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer.

S. Garinet, J. Taieb, A. Zaanan, 2021, European journal of cancer.

Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.

P. Laurent-Puig, F. Puglisi, C. Lepage, 2021, Clinics and research in hepatology and gastroenterology.

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study

C. Lepage, R. Guimbaud, J. Raoul, 2020, British Journal of Cancer.

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

C. Lepage, J. Taieb, R. Coriat, 2018 .

Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial.

C. Lepage, V. Boige, O. Bouché, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).

C. Lepage, F. Caroli-Bosc, J. Taieb, 2020, Clinical colorectal cancer.

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study

C. Lepage, R. Guimbaud, J. Raoul, 2020, British Journal of Cancer.

A. Luciani, I. Sobhani, K. Leroy, 2015, BMC Cancer.

FOxTROT: Are We Ready to Dance?

J. Taieb, M. Karoui, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.

P. Grenier, J. Taieb, T. Poynard, 2012, European journal of radiology.

Usefulness of intraoperative radiofrequency thermoablation of liver tumours associated or not with hepatectomy.

T. de Baère, D. Elias, P. Lasser, 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).

C. Tournigand, D. Vernerey, F. Bonnetain, 2017 .

2355 Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first- line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM)

C. Tournigand, F. Bonnetain, P. Hammel, 2015 .

Adjuvant FOLFOX +/− cetuximab in full RAS and BRAF wildtype stage III colon cancer patients

P. Laurent-Puig, E. Van Cutsem, J. Tabernero, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma: Update of the AGEO cohort

J. Taieb, R. Coriat, J. Bachet, 2019, Annals of Oncology.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

T. Hickish, J. Tabernero, D. Vernerey, 2019, British Journal of Cancer.

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

P. Laurent-Puig, F. Penault-Llorca, J. Tabernero, 2017, European journal of cancer.

Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors

B. Besse, J. Taieb, R. García-Carbonero, 2021, Cancers.

FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty

D. Cairns, J. Taieb, A. Gilbert, 2022, ESMO open.

Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.

E. Van Cutsem, J. Tabernero, M. Fakih, 2023, The New England journal of medicine.

Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug (DT) for patients with advanced hepatocellular carcinoma (HCC).

C. Trépo, J. Taieb, L. Bonyhay, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2019, Journal of Clinical Oncology.

Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.

R. Salazar, P. Laurent-Puig, J. Tabernero, 2017 .

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)

M. Ducreux, F. Lévi, G. Milano, 2017, British Journal of Cancer.

DPYD Genotyping to Predict Adverse Events Following TreatmentWith Fluorouracil-Based Adjuvant Chemotherapy in PatientsWith Stage III Colon Cancer

R. Greil, R. Salazar, P. Laurent-Puig, 2016 .

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.

P. Laurent-Puig, H. Blons, O. Bouché, 2023, European journal of cancer.

Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.

A. Lièvre, J. Taieb, S. Pernot, 2021, Clinics And Research in Hepatology and Gastroenterology.

Genomic profiling of ampullary adenocarcinoma (AA): Insights from a comparative analysis of pancreatic and intestinal adenocarcinoma and opportunities for targeted therapies use.

P. Laurent-Puig, B. Nordlinger, J. Vaillant, 2017 .

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study

P. Laurent-Puig, A. Sauvanet, J. Emile, 2019, British Journal of Cancer.

Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.

C. Borg, Jean-David Fumet, F. Ghiringhelli, 2020 .

Chemotherapy-induced ileitis associated or not with colitis in digestive oncology patients: An AGEO multicentre study.

B. Rance, J. Taieb, C. Broudin, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

A systematic review of minimal length of lroximal margin in gastric adenocarcinoma resection

J. Taieb, A. Zaanan, L. Rebibo, 2023, Langenbeck's Archives of Surgery.

Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study.

P. Laurent-Puig, J. Tabernero, C. Lepage, 2016 .

J. Canon, M. Peeters, G. Pentheroudakis, 2018, British Journal of Cancer.

Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.

S. Olschwang, V. Boige, O. Bouché, 2016 .

Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Y. Bang, J. Taieb, M. Dvorkin, 2020 .

FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review

Jin‐Young Jang, G. Malleo, S. Hoffe, 2023, Annals of Surgical Oncology.

Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase IIIb PRECONNECT study.

E. Van Cutsem, F. Ciardiello, L. Wyrwicz, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study.

E. Van Cutsem, T. Price, J. Seitz, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases.

J. Taieb, B. Landi, O. Pellerin, 2017, Clinics and research in hepatology and gastroenterology.

Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial.

Y. Bang, F. Ciardiello, L. Wyrwicz, 2016 .

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

J Ricke, T Maughan, W. Oyen, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: An AGEO multicenter study.

D. Vernerey, F. Bonnetain, J. Taieb, 2014 .

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

P. Bachellier, C. Borg, D. Vernerey, 2016, BMC Cancer.

O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study

M. Shah, J. Tabernero, M. Fakih, 2021, Annals of Oncology.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

R. Labianca, M. Ducreux, J. Taïeb, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]

J. Taieb, A. Zaanan, 2018, Bulletin du cancer.

[NK cell-based immunotherapy: new prospects and involvement of dendritic cells].

L. Zitvogel, C. Borg, J. Taieb, 2003, Bulletin du Cancer.

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

R. Boidot, C. Borg, A. Bertaut, 2023, Nature Medicine.

Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer.

C. Köhne, M. Peeters, M. Valladares-Ayerbes, 2021, Clinical colorectal cancer.

LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival

J. Berlin, A. Biankin, P. Philip, 2021, Annals of Oncology.

A large multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancers with microsatellite instability.

J. Taieb, R. Coriat, D. Tougeron, 2017 .

Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).

A. Luciani, C. Tournigand, I. Sobhani, 2017 .

[Innate defence against tumor cells: the killer cell IKDC].

L. Zitvogel, N. Chaput, J. Taieb, 2006, Bulletin du cancer.

Atypical cutaneous metastases of poorly cohesive carcinoma of the stomach: Letter to the editor.

J. Taieb, C. Lépine, C. Gallois, 2021, Clinics And Research in Hepatology and Gastroenterology.

Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.

D. Vernerey, J. Taieb, A. de Gramont, 2018, European journal of cancer.

Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials

P. Laurent-Puig, E. Van Cutsem, R. Goldberg, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.

P. Rougier, F. Bonnetain, P. Hammel, 2015 .

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial.

C. Lepage, P. Rougier, M. Hebbar, 2016 .

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).

V. Boige, O. Bouché, F. Ghiringhelli, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

P. Laurent-Puig, F. Sinicrope, A. de Reyniès, 2023, Clinical Cancer Research.

FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.

J. Taïeb, J. Spano, J. Taieb, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Nutrition Support in Pancreatic Cancer: An Expert Statement on Practical Implementation of French Guidelines.

J. Taieb, C. Neuzillet, P. Pessaux, 2023, Clinics and research in hepatology and gastroenterology.

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.

N. Siauve, P. Rougier, J. Taieb, 2014, Clinics and research in hepatology and gastroenterology.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

W. Oyen, R. Labianca, W. Scheithauer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

M. Peeters, M. Valladares-Ayerbes, F. Rivera, 2018, Journal of Cancer Research and Clinical Oncology.

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

M. Ducreux, A. Cazes, C. Borg, 2017, European journal of cancer.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

How best to treat older patients with metastatic colorectal cancer?

J. Taieb, 2019, The lancet. Gastroenterology & hepatology.

6091 POSTER Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)

P. Laurent-Puig, M. Ychou, O. Bouché, 2011 .

Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT) in patients age 65 or older.

D. Ferry, L. Ciuffreda, J. Taieb, 2015 .

V. Heinemann, J. Taieb, A. Sobrero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).

D. Ferry, S. Siena, J. Taieb, 2014 .

FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study

V. Heinemann, G. Prager, J. Taieb, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]

J. Taieb, A. Zaanan, J. Taieb, 2019, Bulletin du cancer.

V. Gebski, P. Gibbs, V. Heinemann, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men

S. Grabar, J. Taieb, H. Péré, 2018, British Journal of Cancer.

Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data

Moreno Ursino, Sarah Zohar, Bruno Landi, 2019, Statistical methods in medical research.

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

E. Tartour, F. Penault-Llorca, N. Radosevic-Robin, 2019, Gastric Cancer.

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.

M. Ducreux, P. Rougier, O. Bouché, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.

A. Lièvre, P. Laurent-Puig, C. Lepage, 2023, European journal of cancer.

Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data.

C. Bokemeyer, J. Tabernero, G. Folprecht, 2012 .

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)

P. Laurent-Puig, N. Siauve, H. Blons, 2017, Clinical Cancer Research.

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)--A randomized phase II trial.

O. Bouché, F. Retornaz, J. Taieb, 2015 .

Advances in management of adjuvant chemotherapy in rectal cancer: Consequences for clinical practice.

C. Durdux, J. Taieb, A. Berger, 2016, Clinics and research in hepatology and gastroenterology.

Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort’

J. Taieb, J. Bachet, S. Pernot, 2016, British Journal of Cancer.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

P. Laurent-Puig, F. Penault-Llorca, J. Tabernero, 2017, European journal of cancer.

[MET signalling pathway and its therapeutic implications in gastrointestinal cancers].

P. Laurent-Puig, J. Taieb, A. Zaanan, 2014, Bulletin du cancer.

C. Tournigand, F. Bonnetain, P. Hammel, 2017, The lancet. Gastroenterology & hepatology.

ADJUVANT FOLFOX4 PLUS OR MINUS CETUXIMAB (CMAB) IN PATIENTS (PTS) WITH KRAS MUTANT (MKRAS) RESECTED STAGE III COLON CANCER (CC). RESULTS FROM THE PETACC8 INTERGROUP TRIAL

R. Salazar, C. Lepage, G. Folprecht, 2012 .

M. Ychou, G. Deplanque, Y. Bécouarn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.